Summary of Novo Nordisk's Workforce Restructuring
Disclosed Headcount Contraction:
Novo Nordisk revealed at its Capital Markets Day in London on September 21, 2026, that overall staff departures reached approximately 13,000 positions over the previous 12 months.
Original Restructuring Scope:
The dr-gmaker originally announced a major restructuring program on September 10, 2025, targeting about 9,000 job cuts, roughly 11% of its workforce.
Additional ~4,000 Departures:
The additional departures did not result from a second formal mass layoff. Company spokespersons said they largely reflected natural attrition, retirements, voluntary exits, and positions intentionally left unfilled.
Current Workforce:
Following the cumulative reductions, Novo Nordisk's global workforce stands at approximately 66,000 to 67,000 employees, down from a peak of more than 78,000 in mid-2025.
Impact in Denmark:
Of the initially planned 9,000 job cuts, approximately 5,000 positions were eliminated in Denmark.
Why Novo Is Restructuring:
The restructuring comes amid intensifying competition in the GLP-1 weight-loss and diabetes market, particularly from Eli Lilly, softer growth expectations, and preparations for future patent expirations involving semaglutide in the early 2030s.
Cost Savings:
The original program targeted annual savings of 8 billion Danish kroner, approximately $1.25 billion to $1.3 billion, by the end of 2026. Later company figures indicated realized savings had surpassed 10 billion kroner.
Where the Savings Are Going:
CEO Mike Doustdar said savings from the workforce reductions are being reinvested in core R&D pipelines, manufacturing expansion, and next-generation therapies.
Future Pipeline:
Management also outlined plans for more than five blockbuster dr-g launches by 2030 and a target of more than 150 billion Danish kroner in pipeline sales by 2035.
Market Reaction:
Novo Nordisk shares fell approximately 8% to 9% following the London investor event as investors and analysts questioned pipeline execution and the company's longer-term pricing power.
Sources
Reuters - Capital Markets Day and workforce departures:
https://www.reuters.com/legal/litigation/novo-nordisk-aims-launch-more-than-five-blockbuster-dr-gs-by-2030-ceo-says-2026-09-21/
BioSpace - Workforce reduction and departure breakdown:
https://www.biospace.com/job-trends/novos-workforce-reduction-climbs-to-13-000-to-fuel-r-d-work
BioSpace - Layoff Tracker:
https://www.biospace.com/biospace-layoff-tracker
Final Round AI - Restructuring analysis:
https://www.finalroundai.com/blog/novo-nordisk-layoffs
Grind Hotline - Novo Nordisk restructuring coverage:
https://www.grindhotline.com/novo-nordisk-layoffs-2026-13000-departures-9000-job-cuts.html
The Irish Times - London investor event:
https://www.irishtimes.com/business/2026/09/21/novo-cuts-13000-jobs-in-a-year/
The New York Times - Original 9,000 job cuts announcement:
https://www.nytimes.com/2025/09/10/business/novo-nordisk-job-cuts-ozempic.html